Immutep Limited
Immutep (NASDAQ:IMMP) is a globally active biotechnology company, listed on the Australian Stock Exchange and on the NASDAQ Global Market in the US. As a leader in personalized bio-therapeutic products for cancer, Immutep is dedicated to leveraging its current technology and expertise to develop innovative treatment options for patients and maximize value to shareholders.
Immutep's main pipeline of products is based on the LAG-3 immune control mechanism which plays a vital role in the regulation of the T cell immune response. The most clinically advanced product is a T cell immunostimulatory factor (APC activator), IMP321, for cancer chemoimmunotherapy which has completed early Phase II trials. A number of additional LAG-3 products including antibodies for immune response modulation in autoimmunity and cancer are being developed by large pharmaceutical partners.
CEO & Executive Director
Immutep Limited
Mr Voigt has more than 20 years of experience in the financial and biotech industry, having joined the Immutep team in 2011 as the General Manager, European Operations based in Berlin, Germany.
In May 2012, he became Immutep ’s Chief Business Officer and in November 2012 its Chief Financial Officer, as well as continuing to focus on its European operations. Having started his career at the Allianz Group working in pension insurances and funds, he moved to net.IPO AG, a publicly listed boutique investment bank in Frankfurt where he was focused on IPOs and venture capital investments. Mr Voigt then worked for a number of years as an investment manager for a midsize venture capital fund based in Berlin, specialising in healthcare. He also gained considerable operational experience while serving in different management roles with Revotar Biopharmaceuticals, Caprotec Bioanalytics and Medical Enzymes AG respectfully, where he handled several successful licensing transactions and financing rounds. Since 2001, Mr Voigt has been a judge and coach in BPW, Germany’s largest regional start-up initiative.
Mr. Voigt has a Masters Degree in Business Administration from the Freie Universität of Berlin.